ClinicalTrials.gg
CompletedNCT00422188Updated Dec 10, 2015

Deoxycholic Acid Injection for the Treatment of Superficial Lipomas

A Phase 1 interventional study of Deoxycholic Acid Injection and Placebo in Lipoma, sponsored by Kythera Biopharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-12-10.

Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this research is to compare the safety and effectiveness of 4 different concentrations of deoxycholic acid injection against a placebo in the treatment of superficial lipomas.

Read the detailed description

A lipoma is a fatty lump typically located on the trunk, shoulder, arms or legs. For the purposes of this study, only lipomas on the trunk, arms, legs, or neck were treated. (Lipomas on the face, wrists, hands, lower portion of the spine, genitals, ankles, or feet were not treated.)

02

Conditions studied

  • Lipoma

Browse trials for

03

In context

Lipoma

22 studies on the registry are indexed under Lipoma; 6 are open to participants now.

This study's enrollment of 16 is below the median of 30 across 17 interventional studies indexed under Lipoma.

Browse Lipoma studies →

Lead sponsor

Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.

First submitted before Kythera Biopharmaceuticals became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • One or more lipomas, based on clinical diagnosis, which are accessible for treatment and assessment, are quantifiable along at least 2 perpendicular diameters, and have the following characteristics:

    • History of slow growth followed by dormancy, and stable for at least 6 months.
    • Greatest length by greatest perpendicular width between 1 and 16 square centimeters, inclusive
    • Discrete, oval to rounded in shape, not hard or attached to underlying tissue
    • Located on the trunk, arms, legs, or neck
  • Stable body weight with a of less than 30 kg/m²
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Absence of significant medical conditions that could affect safety
  • History of surgical treatment for lipomas
  • Treatment with an agent within 30 days before ATX-101 treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Deoxycholic Acid Injection 0.5%

    Participants received 0.5% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.

    Drug: Deoxycholic Acid Injection

  • Experimental
    Deoxycholic Acid Injection 1.0%

    Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.

    Drug: Deoxycholic Acid Injection

  • Experimental
    Deoxycholic Acid Injection 2.0%

    Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.

    Drug: Deoxycholic Acid Injection

  • Experimental
    Deoxycholic Acid Injection 4.0%

    Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.

    Drug: Deoxycholic Acid Injection

  • Placebo comparator
    Placebo

    Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.

    Drug: Placebo

Interventions

  • Administered via intralipomal injection.

    Also known as: ATX-101, Sodium deoxycholate

  • DrugPlacebo

    Administered via intralipomal injection.

06

What researchers measure

Primary outcomes

  1. Assessments of Safety with Laboratory tests

    Time frame: up to 16 weeks

  2. Assessments of Safety with ECG

    Time frame: up to 16 weeks

  3. Assessments of Safety with Medical Evaluations

    Time frame: up to 16 weeks

Secondary outcomes

  1. Lipoma size reduction

    Time frame: up to 16 weeks

07

Study locations

1 site
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00422188
Responsible party
Sponsor
First posted
Jan 15, 2007
Start date
Jan 2007
Primary completion
Nov 2007
Completion
Nov 2007
Last update
Dec 10, 2015

Study contacts

Stacy R. Smith, M.D.
principal investigator · Therapeutics Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deoxycholic Acid

Start the discussion